Current therapy for malignant mesothelioma.
This review briefly summarizes the results of previous systemic (chemotherapy) and local (surgery and radiotherapy) treatment attempted to date for malignant mesothelioma. The prospects for newer modalities, ie molecular and biologic therapies, are also highlighted, including results of both preclinical and early clinical research.
Smythe
W Roy
WR
Multidisciplinary Mesothelioma Thoracic Oncology Program, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, USA. rsmythe@mail.mdanderson.org
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001195:Asbestosis / Q000150:complications; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008654:Mesothelioma / Q000628:therapy*; D010997:Pleural Neoplasms / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000379:methods; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine